

Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GNANLEX

Lisinopril

A. Active patents

S.no.	Title	Assignee	Patent details	Type of patent	Remarks
1	A process for the preparation of 6-(5-chloropyrid-2-yl)-5-(4-methylpiperazin-1-yl)-carbonyloxy-7-oxo-5,6-dihydropyrrolo-[3,4-b]-pyrazine and it's enantiomerically enriched isomer	Mylan Laboratories Limited	App no/Grant no: IN276937(907/CHE/2007) Filing date: 27/04/2007 Grant date: 07/11/2016 Expected expiry date 27/04/2027(Under Extension Period for payment of fees): Form 27: Patent not yet worked in India.	Process for the preparation of Lisinopril dihydrate	Patent Barrier Can be worked around.

B. Pending applications

S.no.	Title	Assignee	Application details	Type of patent	Remarks
1	An improved process for the preparation of lisinopril useful as angiotensin-converting enzyme inhibitors a novel intermediate for the preparation of lisinopril and a process for its preparation	M/S. Neuland laboratories limited	App no: 706/CHE/2003 Filing date : 05/09/2003 Status: Not available (legal status and file wrapper is not available online)	Process for the preparation Lisinopril	No patent barrier even if granted. Can be worked around

C. Expired/Lapsed applications

S.no.	Title	Assignee	Patent/Application details	Type of Patent	Remarks
1	An improved process for purification of l-proline, n2-[(1s)-1-ethoxycarbonyl-3-phenylpropyl]-n6-(trifluoroacetyl)-l-lysyl	Calyx Chemicals And Pharmaceuticals Ltd	App no: 870/MUM/2008 Filing date: 17/04/2008 Status: Deemed to be abandoned U/S 21(1)	Process For Purification Of lisinopril	No patent barrier
2	A novel process for desalination of lisinopril	Calyx Chemicals And Pharmaceuticals Ltd	App no: 2504/MUM/2008 Filing date: 01/12/2008 Status: Deemed to be abandoned U/S 21(1)	Process For Desalination Of Lisinopril	No patent barrier
3	Formulation and evaluation of controlled drug delivery of lisinopril	1. Devgun Manish, 2. Grover Ish, 3. Singh Balvinder	App no: 201711020236 Filing date: 09/06/2017 Status: Deemed to be abandoned U/S 21(1)	Formulation Of Lisinopril	No patent barrier

Commissioned by



Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GNANLEX

Disclaimer:

Search results are up to 21st May 2020

GNANLex's Opinion / Report as hereinabove is to the best of our knowledge, true and accurate as of the date compiled based on available information. However, no guarantee is made as to its accuracy, reliability or completeness. The final user is expected to assume sole liability for any patent infringement that occurs by following our recommendations or using the information given. Before using, user should determine the suitability of the information for his intended use. The risk and liability, if any, in connection therewith, is solely that of the user.

Commissioned by

